The Brand Name OCYL-5 Has Generic Salt :: Procyclidine
OCYL-5 Is From Company Zenith Ph. Priced :: Rs. 19
OCYL-5 have Procyclidine is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Parkinsonism, Drug-induced extrapyramidal syndrome
Drug Dose ::
Oral Parkinsonism and drug-induced extrapyramidal syndrome Adult: As hydrochloride: Initially, 2.5 mg tid, increased gradually by 2.5-5 mg every 2-3 days if required. Maintenance: 10-30 mg/day in 3-4 divided doses. Up to 60 mg daily may be required in some cases. Elderly: Lower doses are required. Dystonia in children Child: 7-12 yr: 1.25 mg tid; 12-18 yr: 2.5 mg tid. For emergency cases, a single dose may be given via IM or IV inj: <2 yr: 0.5-2 mg; 2-10 yr: 2-5 mg and 10-18 yr: 5-10 mg. Parenteral Parkinsonism and drug-induced extrapyramidal syndrome Adult: Emergency cases: IV admin: 5-10 mg, higher doses may be needed; IM admin: 5-10 mg as a single dose, may repeat after 20 minutes if needed, to a max of 20 mg daily. Elderly: Lower doses are required. Contraindication ::
Urinary outflow obstruction, prostatic hyperthrophy, narrow-angle glaucoma, paralytic ileus and pyloric stenosis.
Drug Precautions ::
Patients with diarrhoea. May impair a patient’s ability to perform skilled tasks e.g. driving. May precipitate psychotic episodes in patients with mental disorders. Thyrotoxicosis, heart failure, acute myocardial infarction, hypertension. Childn, elderly. Pregnancy and lactation. Avoid abrupt withdrawal.
Drug Side Effects ::
Excitability, dizziness, hallucinations (seen on abuse), dry mouth, blurred vision, constipation, urinary retention, agitation, restlessness, confusion and convulsions.
Pregnancy category ::
Drug Mode of Action ::
Procyclidine is a tertiary amine antimuscarinic which acts by blocking excess acetylcholine at cerebral synapses. It also exhibits direct antispasmodic effect on smooth muscle.
Drug Interactions ::
Increased plasma concentrations w/ paroxetine. Enhanced anticholinergic action w/ MAOIs and other anticholinergic drugs. Reduced therapeutic effect w/ cholinergic drugs. May antagonise the effect of parasympathomimetic agents. May reduce the absorption and therapeutic effect of sublingual or buccal nitrate tab. May reduce the efficacy of levodopa. May antagonise the GI effects of cisapride, domperidone and metoclopramide. May potentiate the vagolytic effects of quinidine. May reduce the absorption of ketoconazole.